| Description | The product SIRGT00001WQ is a type of small interfering RNA (siRNA) that targets A1BG gene and regulates the expression of gene. The siRNA interferes with the expression of A1BG gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. It has The product SIRGT00001WQ is a type of small interfering RNA (siRNA) that targets A1BG gene and regulates the expression of gene. The siRNA interferes with the expression of A1BG gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More | Creative Biolabs' Neuropathy Frozen Tissue Panels are designed for the study of Alzheimer's disease, Parkinson's disease, dementia, multiple sclerosis, progressive supranuclear palsy (PSP) and depression. | This product GTTS-WQ5787MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research. | This product GTTS-WK14445MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the AK124399 protein. This product can be used in CD1C-CD141- dendritic cell-related researches. | Recombinant Norovirus GII.4 Virus-like Particles (NoV GII.4 VLPs) are produced in Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes Recombinant Norovirus GII.4 Virus-like Particles (NoV GII.4 VLPs) are produced in Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. NoV GII.4 VLPs can be used in the development of NoV GII.4 diagnostics and in vaccine development and R&D (including use as an immunogen).... Read More |